16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation.

      Neuroscience
      Analysis of Variance, Animals, Benzoxazoles, pharmacology, Bromodeoxyuridine, metabolism, Cell Proliferation, drug effects, Cells, Cultured, Dose-Response Relationship, Drug, Embryo, Mammalian, Exploratory Behavior, Hippocampus, physiology, Immobility Response, Tonic, Injections, Intraventricular, methods, Intracellular Signaling Peptides and Proteins, administration & dosage, Male, Mice, Nerve Tissue Proteins, Neurogenesis, Neuropeptide Y, Neuropeptides, Neurotransmitter Agents, Orexin Receptors, Receptors, G-Protein-Coupled, Receptors, Neuropeptide, Stem Cells, Urea, analogs & derivatives

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A decrease in orexin-A (OX-A) levels has been reported to be associated with depression. It is also well known that stress and depression can disrupt neurogenesis in the dentate gyrus of the hippocampus; however, it is unclear how OX-A is involved in depression and/or neurogenesis. In the present study, we investigated the effect of i.c.v. administration of OX-A on the forced swimming test (FST), an accepted behavioral screen of antidepressant-like activity, and on the cell proliferation with bromodeoxyuridine (BrdU) in the dentate gyrus at 4 days after i.c.v. administration of OX-A. OX-A administration (140 pmol/mouse) led to a significant reduction in animal immobility in the FST, without affecting spontaneous locomotor activities or serum corticosterone levels. In addition, the number of BrdU-positive cells in the dentate gyrus was significantly increased in OX-A-treated mice in vivo; however, OX-A did not affect the percentage of doublecortin-positive cells in the dentate gyrus. The proliferation of neural progenitor cells derived from rat fetal brain was not affected by OX-A treatment in vitro, and the orexin receptor 1 (OXR1) protein was not expressed in these cells. Treatment with the OXR1 antagonist SB-334867 (30 mg/kg, i.p.) blocked both the OX-A-induced decrease in the immobility of FST and increase in BrdU-positive. Moreover, the OX-A-induced increase in neuropeptide Y (NPY)-positive cells in the hilus of the dentate gyrus was blocked by SB-334867. These results suggest that OX-A induces an antidepressive-like effect, at least in part, via the enhancement of cell proliferation in the dentate gyrus. These effects of OX-A also may be partly relevant to the regulation of the NPY system in the hilus of the dentate gyrus.

          Related collections

          Author and article information

          Comments

          Comment on this article